GREENVILLE, S.C., Feb. 13 /PRNewswire-FirstCall/ -- Signalife, Inc. a medical device company focused on the detection of cardiovascular disease through continuous ECG signal monitoring, today announced that it will participate in the Heart Rhythm Society Meeting 2006, 27th Annual Scientific Session with physicians from the prestigious Cleveland Clinic. The presentation titled “A Novel Portable Wireless Multi-channel ECG and Intracardiac Recording System” is scheduled for May 20th at the Boston Convention & Exhibition Center in Boston, MA. Presenters include Dr. Mauricio Arruda of Cleveland Clinic and Budimir S. Drakulic, PhD, CTO of Signalife, Inc.
Heart Rhythm Society is the international leader in science, education, and advocacy for cardiac arrhythmia professionals and patients, and the primary information resource on heart rhythm disorders.
“We have made great progress in the development and validation of our high-fidelity signal processing platform for biomedical signal recordings,” said Dr. Budimir S. Drakulic, Signalife’s Chief Technology Officer. “In our collaboration with Dr. Andrea Natale and Dr. Arruda of the electrophysiology laboratory at Cleveland Clinic, we were able to successfully apply our patented technology to intracardiac recordings during catheter ablation procedures. This conference will provide a great opportunity for Signalife to introduce its technology to the Heart Rhythm Society audience.”
“We are pleased with initial results obtained with the new wireless multi-channel ECG and Intracardiac recording system from Signalife,” said Dr. Natale, Co-Section Head of Pacing and Electrophysiology in the Cleveland Clinic Department of Cardiovascular Medicine.
About Cleveland Clinic
Cleveland Clinic, located in Cleveland, Ohio, is a not-for-profit multispecialty academic medical center that integrates clinical and hospital care with research and education. Cleveland Clinic was founded in 1921 by four renowned physicians with a vision of providing outstanding patient care based upon the principles of cooperation, compassion and innovation. U.S. News & World Report consistently names Cleveland Clinic as one of the nation’s best hospitals in its annual “America’s Best Hospitals” survey. Approximately 1,500 full-time salaried physicians at Cleveland Clinic and Cleveland Clinic Florida represent more than 100 medical specialties and subspecialties. In 2004, patients came for treatment from every state and 100 countries. Cleveland Clinic website address is www.clevelandclinic.org.
About Signalife, Inc.
Signalife, Inc. is a medical device company focused on the detection of cardiovascular disease through continuous ECG signal monitoring. The company’s goal is to become the premier global provider of cardiovascular disease monitoring products. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory environment. Signalife’s revolutionary FDA-approved patented electrocardiograph (ECG) monitoring system called Fidelity 100 allows for the recording of a high-quality ECG signal from ambulatory cardiac patients. The Fidelity 100 will address a portion of $400 billion cardiac disease market.
Signalife, Inc. is traded on the American Stock Exchange under the symbol SGN. More information is located at http://www.signalife.com.
Caution Regarding Forward-Looking Statements
Statements in this release that are not strictly historical are “forward- looking” statements. Forward-looking statements involve known and unknown risks, which may cause Signalife’s actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of new products or services, failure to obtain federal or state regulatory approvals governing medical devices, monitoring and other related services or products, inability to obtain physician, patient or insurance acceptance of Signalife’s products or services, adverse equity- market conditions and declines in the value of Signalife’s common stock, and the unavailability of financing to complete management’s plans and objectives. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife’s filings with the Securities and Exchange Commission.
Signalife, Inc.
CONTACT: Corporate Communications, Claire Mouton LaFrance, Director ofMarketing & Communications, Signalife, +1-864-233-2300,clafrance@signalife.com; Media, Adam J. Handelsman, SVP & GM,+1-212-999-5585 ext. 202, ahandelsman@5wpr.com, or Investor, Mark Cohen,Vice President, 5W Public Relations IR, +1-212-999-5585, mcohen@5wpr.com,both of 5W Public Relations, for Signalife, Inc.
